Outlook Sets Out Plans For Ophthalmic Bevacizumab In Europe
As Formal European Approval Arrives For Lytenava, Firm Sets Launch Date
Executive Summary
Outlook Therapeutics has revealed more details of its European launch strategy for its Lytenava ophthalmic bevacizumab following the product’s formal European Commission approval.